Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $17

Following the company's third-quarter financial results, analyst firm Wedbush updated its outlook on BioCryst Pharmaceuticals. The firm maintained its Outperform rating on the stock while adjusting the price target to $17 from the previous $18. This action reflects the firm's ongoing assessment of the company's performance and market position.